“P016 | EFFECTIVENESS AND SAFETY OF MONTHLY VERSUS QUARTERLY FREMANEZUMAB FOR MIGRAINE PREVENTION: A 12 MONTHS ITALIAN, MULTICENTER, REAL-LIFE STUDY: A. Antoniazzi1, E. Ratto1, I. Cetta1, A. Visentini1|2, L. Consuma1|2, F. Genovese1|2, L. Zanandrea1|2, C. Lovati3, S. Cevoli4, V. Favoni4, F. Vernieri5|6, C. Altamura5|6, B. Colombo1, M. Filippi1|2, R. Messina1|2 | 1Headache Center, Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; 2Vita-Salute San Raffaele University, Milan, Italy; 3Headache Center, L. Sacco University Hospital, Milan, Italy; 4IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy; 5Unit of Headache and Neurosonology, Department of Medicine and Surgery, University Campus Bio-Medico di Roma, Italy; 6Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy” (2026) Confinia Cephalalgica, 36(s1). doi:10.4081/cc.2026.15972.